How much does a box of Obeticholic acid cost and what is the price?

Obeticholic acid(Obeticholic acid) is an innovative drug used to treat chronic liver diseases and is a farnesoid X receptor (FXR) agonist. The drug was developed by Intercept Pharmaceuticals in Europe and the United States and marketed under the brand name Ocaliva. It is mainly used to treat primary biliary cholangitis (PBC). However, obeticholic acid has not yet been approved for marketing in mainland China, so it cannot be included in the national medical insurance directory, and there is no official domestic selling price. If patients want to use the drug, they usually need to obtain it through overseas medical institutions or formal channels.

In overseas markets, the common specifications of obeticholic acid original drug are5 mg and 10 mg tablets, 30 tablets per box. Based on international drug retail prices and exchange rate conversions, the price is usually as high as more than 20,000 yuan per box. Prices vary depending on country, pharmacy channel, medical insurance policy and exchange rate fluctuations. Due to the high research and development costs of original drugs and limited market supply, prices have always remained high. In contrast, pharmaceutical companies in some countries have launched generic versions, such as Laos' ASEAN Pharmaceuticals, Bangladesh's Beacon and India's Mylan. The composition of these generic drugs is consistent with that of the original drugs. The main active ingredient is obeticholic acid. The efficacy is similar, but the price is more affordable, ranging from hundreds to thousands of yuan per box. The specific price is affected by the exchange rate and import channels.

As a liver disease treatment drug that has attracted international attention, the high price of obeticholic acid not only reflects the complexity of new drug development, but also reflects the scarcity of demand for treatment of specific diseases. As the international generic drug market matures, it is expected that its prices will be further reduced in the future, thereby benefiting more patients. For domestic patients, they can pay attention to the developments of the National Center for Drug Evaluation. Once obeticholic acid is approved for marketing in China, its price and medical insurance policy will be more accessible, and its clinical use will be more popular.

Reference materials:https://en.wikipedia.org/wiki/Obeticholic_acid